Which intravitreal anti-VEGF agent has been associated with a distinct safety signal of retinal vasculitis and intraocular inflammation, leading regulatory authorities to issue specific warnings?

• A Ranibizumab
• B Faricimab
• C Bevacizumab
• D Brolucizumab ✓

Explanation

Brolucizumab, a single-chain antibody fragment approved for wet AMD, was linked post-marketing to cases of intraocular inflammation including retinal vasculitis and retinal artery occlusion, prompting boxed warnings and careful case selection. Ranibizumab, bevacizumab and faricimab have long safety records without this characteristic vasculitis signal. Recognition of this entity is essential because it mandates immediate discontinuation and referral.

Reference: Kanski's Clinical Ophthalmology, 10th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.